Schering-Plough/Enzon PEG-Intron
Executive Summary
Phase III clinical trial for treatment of chronic myelogenous leukemia shows PEG-Intron did not meet efficacy endpoint, Enzon discloses in Aug. 15 filing with the Securities & Exchange Commission. "The efficacy results for PEG-Intron did not meet the protocol-specified statistical criteria for non-inferiority," the filing states. "The results of this study have not been published, and are not publicly available at this time"